THERAPEUTIC CLASS

Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients With Hepatic Decompensation: A Randomized, Open-Label Study

---

A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score
7). Adult subjects were randomized and treated (n 5 191) with entecavir 1.0 mg or adefovir 10 mg daily for up to 96 weeks from the date of last subject randomization.
Subjects were positive or negative for hepatitis B e antigen and experienced or naive for treatment with nucleos(t)ide analogues.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Gastrointestinal & Hepatobiliary System
Atevir

Specific Detail Info

HEPATOLOGY 2011;54:91-100

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment